Biora Therapeutics Application for Ulcerative Colitis Treatment Gets FDA Clearance
30 Novembre 2023 - 11:29PM
Dow Jones News
By Denny Jacob
Biora Therapeutics' investigational new drug application for
moderate to severe ulcerative colitis treatment BT-600 was cleared
by the Food and Drug Administration.
Ariella Kelman, chief medical officer of the biotech company,
said Biora will complete activities required by the FDA and trial
site prior to enrolling the first subject in its Phase 1 clinical
trial in the U.S. in the coming weeks.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
November 30, 2023 17:14 ET (22:14 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Grafico Azioni Biora Therapeutics (NASDAQ:BIOR)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Biora Therapeutics (NASDAQ:BIOR)
Storico
Da Giu 2023 a Giu 2024